AttardLab

Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.

[AttardLab @AttardLab]

Question: if an mHSPC patient has a PSA decline on primary treatment to <0.2ng/mL, does the volume of metastases at diagnosis make a difference? Answer in our latest STAMPEDE trial manuscript https://t.co/eNTF27Vaag

[AttardLab @AttardLab]

How can we prevent the aggressive disease course of PTEN loss/inactive cancers? ⁦@EmilyGrist1⁩ ⁦@ChrisSweens1⁩ https://t.co/GiQQNVJhxr

[Alison Tree 💙 @alison_tree]

About time! Good news for those men currently paying out of pocket for Abiraterone and great news for all men who will benefit in future. Well done @ProstateUK for your relentless campaigning to right this wrong.

[pas_rescigno @PasRescigno]

Quick overview of news in Prostate Cancer from Esmo with @Ecastromarcos @AttardLab and Axel Heidenreich
Please follow https://t.co/6PRoCYDJd2

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

🚨 Big News from #APCCC26 🚨
APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer!
Full details & submission 👉 https://t.co/zkUcxACO1F

📅 Key Dates:
🔹 Submission opens: 1 Sept 2025
🔹 Deadline: 14 Nov 2025, 23:59 CET
🔹 Notifications: 19 Dec 2025

✅ Complimentary registration for presenting authors. ✅ Travel grants available for LMIC investigators.
✅ Selected abstracts will be presented as posters in Lugano (30 Apr–1 May 2026).

Categories:
Advanced prostate cancer
Side effects & QoL/PROs
Global access to therapies

@Silke_Gillessen & @AOmlin
@OncoAlert 🚨
@fabioturco92
@Prof_IanD
@drjefstathiou
@Prof_Nick_James
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
@cdanicas
@Ecastromarcos
@mdesantis234
@nachoduranm
@drlouiseemmett
@stefanofanti4
@fontev1
@Nicola_Fossati
@marty_gleave
@ProfKHerrmann
@DrMHofman
@BarbaraJereczek
@ravikanesvaran
@FacsRaja
@LoebStacy
@quimmateo
@DrRanaMcKay
@amerseburger
@CaPsurvivorship
@declangmurphy
@DrPaulNguyen
@WilliamOhMD
@piet_ost
@DrSpratticus
@cnsternberg
@DrYukselUrun
@DrChoueiri
@tompowles1
@brian_rini

Ping
@nataliagandur
@bavilima
@yekeduz_emre

[silke gillessen @Silke_Gillessen]

The mHSPC space becomes more and more interesting! Come and participate in the discussions @APCCC_Lugano register via https://t.co/fPN1UjMfsX!

[Michael Hofman @DrMHofman]

@AzadOncology asking the question- do all patients need six cycles of Lu-PSMA in #PSMAaddition? Showing a nice example of complete response after two cycles on #UpFrontPSMA

[Oscar Tahuahua @OscarTahuahua]

CAPItello-281
In de novo PTEN-deficient mHSPC (poor prognosis), capivasertib + abiraterone ↑ rPFS vs pbo + abiraterone (33.2 vs 25.7 mo; HR 0.81; P=0.034), OS immature. ↑ PTEN loss correlated with ↑ benefit; POTENTIAL for now

With Amplitude trial paving the way, NGS is key in mHSPC

How should we integrate this combo when triplet is already available?
@OncoAlert @myESMO #ESMO25

[AttardLab @AttardLab]

Publication of CAPItello-281 Ph 3 trial in @Annals_Oncology at end of @fizazi_karim #ESMO25 👍https://t.co/yL1UyK2quR

[AttardLab @AttardLab]

@GIZZIMarcoMd Decipher high is the sole BM we pre-defined and had a stat sig p value for an interaction with doce effect. Ie prediction. But I agree that prognostic tests are imp - if patient will not progress, no benefit from doce

[AttardLab @AttardLab]

STAMPEDE update at #ESMO25today at noon. Landmark analysis of 7,129 pts shows PSA ≤0.2 ng/mL by 6–12 weeks strongly predicts OS in HSPC. Prognostic value modified by metastatic volume & nodal status. Abiraterone ± enzalutamide delivers deepest PSA responses & best survival.

[Rana McKay, MD, FASCO @DrRanaMcKay]

Wonderful discussion by ⁦@Prof_Nick_James⁩ on EnzaRad highlighting the differences between Stampede. Lower risk group enrolled and differential effect of ARPI in higher risk group. #ESMO25 ⁦@myESMO⁩ ⁦@OncoAlert⁩

[AttardLab @AttardLab]

EnzaRad P3 trial confirms boundary of patient benefit sits somewhere between STAMPEDE ultra HR and NCCN HR. Working together we will use BM to define this #ESMO25

[Deborah Mukherji @dmukherji]

#ESMO25 #challengeYourExpert @AttardLab @UrsulaVogl @myESMO #ProstateCancer

[AttardLab @AttardLab]

Check out: https://t.co/M7w1LItyMN

[Tom Powles @tompowles1]

ALBAN #ESMO25 (atezolizumab/BCG vs BCG in MIBC) @Annals_Oncology did not ⬆�� EFS (HR0.97) unlike sasalimab & durvalumab in a similar setting. The drugs seem similar in metastatic UC so was it trial design making it different from other ICIs? EFS was defined differently.

[AttardLab @AttardLab]

🧪Sequential liquid biopsies reveal ctDNA features and dynamics linked to survival & resistance in advanced #ProstateCancer patients treated with cabazitaxel.
🧬 cell cycle gene amplification associates with taxane resistance
🤝Results from an international collaborative effort

[AttardLab @AttardLab]

Our latest manuscript with #demichelislab - detailed analysis of ctDNA sequentially collected from metastatic prostate cancer pts receiving cabazitaxel. https://t.co/h9l9XIuuYG

[AttardLab @AttardLab]

#EMUC promising to be a great meeting

[AttardLab @AttardLab]

Exciting